We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+12.33%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$740M
AUM Growth
-$43.3M
Cap. Flow
-$86.3M
Cap. Flow %
-11.66%
Top 10 Hldgs %
29.49%
Holding
104
New
10
Increased
27
Reduced
49
Closed
9

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.8M
2
GILD icon
Gilead Sciences
GILD
+$9.89M
3
COR icon
Cencora
COR
+$7.8M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$6.72M
5
FLXN
Flexion Therapeutics, Inc.
FLXN
+$6.41M

Top Sells

Rank Stock Value
1
NKTR icon
Nektar Therapeutics
NKTR
+$20.2M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$14.8M
3
ABMD
Abiomed Inc
ABMD
+$10M
4
AET
Aetna Inc
AET
+$9.86M
5
CVS icon
CVS Health
CVS
+$9.76M

Sector Composition

Rank Sector Weight
1 Healthcare 90.07%
2 Financials 0.19%
3 Technology 0.17%
4 Energy 0.14%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LUMO
76
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.47M 0.2%
20,116
+9,005
+81% +$745K
KERX
77
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.41M 0.19%
302,157
-97,843
-24% -$539K
STAA icon
78
STAAR Surgical
STAA
$1.21B
$1.18M 0.16%
76,256
-13,744
-15% -$204K
NVRO
79
DELISTED
NEVRO CORP.
NVRO
$1.05M 0.14%
15,145
-114,855
-88% -$9.19M
TTPH
80
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$1.01M 0.14%
+8,045
New +$1.03M
RARX
81
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$922K 0.12%
108,451
-11,246
-9% -$138K
HAL icon
82
Halliburton
HAL
$26.6B
$545K 0.07%
11,144
– –
RGLS
83
DELISTED
Regulus Therapeutics
RGLS
$513K 0.07%
4,107
-726
-15% -$91.9K
JPM icon
84
JPMorgan Chase
JPM
$950B
$483K 0.07%
4,518
-1,123
-20% -$114K
XOM icon
85
ExxonMobil
XOM
$634B
$476K 0.06%
5,696
– –
WFC icon
86
Wells Fargo
WFC
$264B
$463K 0.06%
7,635
-1,018
-12% -$57.5K
JHG
87
DELISTED
Janus Henderson
JHG
$456K 0.06%
+11,906
New +$429K
ADVM
88
DELISTED
Adverum Biotechnologies
ADVM
$445K 0.06%
12,701
-2,700
-18% -$88.8K
MSFT icon
89
Microsoft
MSFT
$3.71T
$410K 0.06%
4,793
– –
PFE icon
90
Pfizer
PFE
$153B
$377K 0.05%
10,985
– –
F icon
91
Ford
F
$55.7B
$355K 0.05%
28,404
– –
QCOM icon
92
Qualcomm
QCOM
$176B
$344K 0.05%
5,368
– –
BUD icon
93
AB InBev
BUD
$165B
$313K 0.04%
2,806
– –
IBM icon
94
IBM
IBM
$224B
$271K 0.04%
1,847
– –
GEN icon
95
Gen Digital
GEN
$17.5B
$263K 0.04%
9,359
– –
CVS icon
96
CVS Health
CVS
$122B
– –
-120,000
Closed -$9.76M
MRK icon
97
Merck
MRK
$318B
– –
-94,320
Closed -$5.76M
NVO
98
Novo Nordisk
NVO
$209B
– –
-160,000
Closed -$3.85M
SNY icon
99
Sanofi
SNY
$104B
– –
-130,000
Closed -$6.47M
RAD
100
DELISTED
Rite Aid Corporation
RAD
– –
-101,950
Closed -$4M
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q4 2017 Portfolio in Review

As of Q4 2017, Rhenman & Partners Asset Management held 104 positions worth $740M, down 5.5% from $783M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rhenman & Partners Asset Management withdrew a net $86.3M in Q4 2017, closing 9 positions and reducing 49 holdings. Its most notable exit was Aetna Inc, an estimated $9.86M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier, followed by Financials and Technology.

Against the trend, Rhenman & Partners Asset Management opened a new position in Acadia Pharmaceuticals worth $10.2M.

  • Rhenman & Partners Asset Management's largest Q4 2017 buy was Acadia Pharmaceuticals: 338,882 shares worth $10.2M.
  • Rhenman & Partners Asset Management added most to Gilead Sciences in Q4 2017, an estimated $9.89M increase.
  • Rhenman & Partners Asset Management's biggest Q4 2017 reduction was Nektar Therapeutics, cutting an estimated $20.2M.
  • Rhenman & Partners Asset Management fully exited Aetna Inc in Q4 2017, selling an estimated $9.86M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 29% of its $740M portfolio in Q4 2017.
  • Rhenman & Partners Asset Management opened 10 new positions and closed 9 in Q4 2017.
  • Rhenman & Partners Asset Management's portfolio value fell 5.5% quarter-over-quarter to $740M.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2017, filed 19 Jan 2018.